Emerging research progress on Epstein-Barr virus-related clinical diseases (PubMed, Zhonghua Yu Fang Yi Xue Za Zhi) - Oct 19, 2026 - "In terms of treatment, antibody based B-cell depletion therapy (such as rituximab) can effectively prevent post-transplant lymphoproliferative diseases and demonstrate good efficacy in treating progressive multiple sclerosis; Immune checkpoint inhibitors have shown outstanding efficacy in EBV associated gastric cancer and Hodgkin lymphoma; Allogeneic hematopoietic stem cell transplantation has increased the long-term survival rate of chronic active EB virus disease to 55% to 65%, and has resulted in a 5-year overall survival rate of 48.7% for adult EBV related hemophagocytic lymphohistiocytosis. In terms of prevention, preventive vaccines targeting gp350 and gH/gL, as well as therapeutic mRNA vaccines targeting LMP2, have entered the clinical trial stage. The above progress provides new directions for precise diagnosis,treatment, and basic research of EBV related diseases."
IO biomarker • Journal • Review • Bone Marrow Transplantation • CNS Disorders • Epstein-Barr Virus Infections • Gastric Cancer • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Hodgkin Lymphoma • Immunology • Infectious Disease • Lymphoma • Multiple Sclerosis • Nasopharyngeal Carcinoma • Oncology • Rare Diseases • Solid Tumor • Transplantation
|
|
M Zheng; Q Yin; T J Li; Y F Cui; Z Y Hong
|